-
2026-04-21
Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal
-
2026-03-12
Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China
-
2026-01-27
Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chronic obstructive pulmonary disease
-
2026-01-23
Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China
-
2025-06-25
Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD
-
2025-02-07
Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China
-
2024-09-23
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia
Nuance Pharma announced that it has agreed with Altamira Medica Ltd. to extend the territory covered by the exclusive license and distribution agreement for Bentrio® nasal spray by several countries across South East and East Asia.
-
2024-09-23
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
Altamira Medica Ltd. has agreed with its partner Nuance Pharma to extend the territory covered by their exclusive license and distribution agreement for Bentrio® nasal spray by several countries across South East and East Asia.
Contact PR
